In the third quarter of 2024, the FDA ’s official website updated the GRAS status of 13 products. All them are still under review.
This article provides a summary of the US FDA GRAS acceptance and approval status in the third quarter of 2024, for the information and reference of businesses.
Pending substances in the third quarter of 2024
|
S.N. |
GRN No. |
Substance |
Notifier |
|
1 |
Hangzhou Viablife Biotech Co, Ltd. (China) |
||
|
2 |
Rebaudioside M from a modified strain of Escherichia coli BL21(DE3) |
Oobli, Inc. (U.S.) |
|
|
3 |
Rebaudioside M from a modified strain of Escherichia coli BL21(DE3) |
Sichuan Ingia Biosynthetic Co., Ltd.（China） |
|
|
4 |
Algal oil (≥35% docosahexaenoic acid) from Schizochytrium sp. FJRK-SCH3 |
Runke Bioengineering (Fujian) Co., Ltd. (China) |
|
|
5 |
Fungal oil (≥38% arachidonic acid (ARA)) from Mortierella alpina FJRK-MA01 |
Runke Bioengineering (Fujian) Co., Ltd. (China) |
|
|
6 |
AB Enzymes, Inc. (U.S.) |
||
|
7 |
Shandong Starlight So True Biological Technology Co., Ltd (China) |
||
|
8 |
Bubs Australia Limited (U.S.) |
||
|
9 |
Omega Yeast Labs, LLC (U.S.) |
||
|
10 |
Shanghai EGT Synbio Group Co., LTD (China) |
||
|
11 |
Mitsubishi Chemical Corporation (Japan) |
||
|
12 |
Sichuan Ingia Biosynthetic Co., Ltd. (China) |
||
|
13 |
Partially hydrolyzed eggshell membrane powder derived from chicken eggs |
ESM Technologies, LLC (U.S.) |
Source: The inventory of GRAS notices.
If you need any assistance or have any questions, please get in touch with us via service@cirs-group.com.
Further Information
Summary of US FDA GRAS Acceptance and Approval Status in the First Quarter of 2024
Summary of US FDA GRAS Acceptance and Approval Status in the Second Quarter of 2024
